EP3672574A2 - Compositions de poudre sèche à inhaler - Google Patents

Compositions de poudre sèche à inhaler

Info

Publication number
EP3672574A2
EP3672574A2 EP18869456.6A EP18869456A EP3672574A2 EP 3672574 A2 EP3672574 A2 EP 3672574A2 EP 18869456 A EP18869456 A EP 18869456A EP 3672574 A2 EP3672574 A2 EP 3672574A2
Authority
EP
European Patent Office
Prior art keywords
dry powder
powder composition
mannitol
inhalation according
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18869456.6A
Other languages
German (de)
English (en)
Inventor
Ali TÜRKYILMAZ
Devrim Celik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Publication of EP3672574A2 publication Critical patent/EP3672574A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the invention relates to dry powder pharmaceutical compositions and inhalers comprising them which are used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive airway diseases.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • DPIs dry powder inhalers
  • these goals can be met with a suitable powder formulation, an efficient metering system, and a carefully selected device. Dry powder inhalers are well known devices for administering pharmaceutically active agents to the respiratory tract to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • compositions for inhalation used in the treatment of obstructive airway diseases can comprise various active agents such as long acting muscarinic antagonists (LAMA), long acting beta agonists (LABA), short acting beta-2 agonists (SABA) and corticosteroids.
  • LAMA long acting muscarinic antagonists
  • LABA long acting beta agonists
  • SABA short acting beta-2 agonists
  • corticosteroids corticosteroids
  • Inhaled corticosteroids reduce inflammation in the airways that carry air to the lungs (bronchial tubes) and reduce the mucus made by the bronchial tubes which makes easier to breathe.
  • Fluticasone is the most commonly used corticosteroid in the dry powder formulations for inhalation.
  • Fluticasone furoate which is a salt of fluticasone, is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity.
  • Fluticasone furoate is available as a combination product with vilanterol, under the tradename Breo Ellipta®. Its use is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
  • Beta2-agonists are used only in combination with a corticosteroid to treat asthma. They are used in a metered-dose or dry powder inhaler. They relax the smooth muscles lining the airways that carry air to the lungs (bronchial tubes). This allows the tubes to stay open longer and makes breathing easier.
  • Vilanterol is a selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma.
  • VAA beta2-adrenergic agonist
  • Vilanterol is also approved for use in combination with umeclidinium bromide as Anoro Ellipta®. It is indicated for the long term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
  • muscarinic antagonists formerly known as anticholinergics, cause bronchodilation with a duration of action of over 24 hours and are used once daily.
  • Umeclidinium which is a long-acting muscarinic antagonist (LAMA), blocks the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function.
  • LAMA long-acting muscarinic antagonist
  • DPI formulations consist of micronized drug blended with larger carrier particles, which enhance flow, reduce aggregation, and aid in dispersion.
  • a combination of intrinsic physicochemical properties, particle size, shape, surface area, and morphology affects the forces of interaction and aerodynamic properties, which in turn determine fluidization, dispersion, delivery to the lungs, and deposition in the peripheral airways.
  • Small drug particles are likely to agglomerate. Said coagulation can be prevented by employing suitable carrier or carrier mixtures. It also assists in controlling the fluidity of the drug coming out of the carrier device and ensuring that the active ingredient reaching to lungs is accurate and consistent.
  • difference of the particle sizes between the carrier and the drug is important in order to optimize the cohesive forces and also to ensure the content uniformity.
  • mannitol is also suggested as carrier instead of lactose.
  • the patent application numbered EP2682097A2 reveals disadvantages rising with the excess use of lactose in inhalation formulations and highlights the use of a carrier other than lactose, namely mannitol.
  • lactose cannot be used for compounds that interact with the reducing sugar function of the lactose.
  • Such drugs are the ones having amine groups, as described above, especially the ones having primary or secondary amine.
  • the use of mannitol seems reasonable; however, mannitol also has its own disadvantages in case of misuse or overuse.
  • EP2682108A2 the use of a tertiary material such as magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sodium benzoate or their mixtures to provide stability; especially magnesium stearate is suggested to improve the moisture resistance of the powder formulation.
  • a tertiary material such as magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sodium benzoate or their mixtures to provide stability; especially magnesium stearate is suggested to improve the moisture resistance of the powder formulation.
  • Moisture in the air is one of the challenges while improving DPIs since it causes the dry powder to clump together and clog the inhaler. This is a potential problem especially for capsule and blister based DPI products, where any moisture ingress occurring during storage may change the chemical behavior and influence the long-term performance of the product. It can also lead to other crucial problems such as the failure in the dosage accuracy present in each cavity or capsule and the decrease in the stability and in the effectiveness of the treatment.
  • the selection of the active agents, suitable carriers and probable other excipients for these active agents, and also their ratios in the formulation has a significant effect on the hygroscopic behavior of the total powder mixture.
  • the prior art has not put any emphasis on these alternative solutions.
  • DPI formulation comprising a ternary combination of active agents selected from the group comprising corticosteroids, long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), which is free of magnesium stearate and which also ensure high stability, fluidity, content uniformity and dosage accuracy.
  • active agents selected from the group comprising corticosteroids, long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), which is free of magnesium stearate and which also ensure high stability, fluidity, content uniformity and dosage accuracy.
  • the main object of the present invention is to obtain dry powder inhalation combinations applicable in obstructive airway diseases, comprising active agents selected from the group comprising corticosteroids, long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
  • active agents selected from the group comprising corticosteroids, long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
  • Another object of the present invention is to obtain inhalation combinations comprising active agents which are hygroscopically convenient.
  • Another object of the present invention is to obtain inhalation combinations comprising fluticasone or a pharmaceutically acceptable salt thereof, vilanterol or a pharmaceutically acceptable salt thereof and umeclidinium or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to obtain inhalation combinations comprising two types of carrier.
  • Another object of the present invention is to obtain inhalation combinations comprising lactose and mannitol as carriers. Another object of the present invention is to obtain inhalation combinations comprising lactose having fine particles and mannitol having coarse particles as carriers.
  • Another object of the present invention is to obtain inhalation combinations free of stearates and amino acids.
  • Another object of the present invention is to obtain inhalation combinations having appropriate carrier particle size ratios and carrier weight ratios ensuring improved moisture resistance, high stability and high fluidity.
  • Another object of the present invention is to obtain inhalation combinations facilitating filling process into the blister pack or the capsule and accordingly enhancing filling rate.
  • Another object of the present invention is to obtain inhalation combinations having appropriate particle size and ratios of both carriers and active agents ensuring content uniformity and dosage accuracy in each blister or capsule.
  • Another object of the present invention is to obtain inhalation combinations having appropriate particle size and ratios of both carriers and active agents ensuring that effective doses of active agents reach the alveoli.
  • a further object of the present invention is to obtain inhalation combinations which can be administered in blister pack or in capsule with an inhaler (inhalation device).
  • a further object of the present invention is to obtain a blister pack filled with the above mentioned dry powder inhalation combinations.
  • a further object of the present invention is to obtain a capsule filled with the above mentioned dry powder inhalation combinations.
  • a further object of the present invention is to obtain an inhaler which is applicable with the above-mentioned blister pack or the above-mentioned capsule.
  • the present invention relates to dry powder compositions for inhalation, which are used in the treatment of chronic obstructive pulmonary disease and asthma in mammals especially in humans, comprising a corticosteroid or pharmaceutically acceptable salt thereof, a long-acting beta2-adrenergic agonist (LABA) or pharmaceutically acceptable salt thereof and a long-acting muscarinic antagonist (LAMA) or pharmaceutically acceptable salt thereof in combination.
  • a corticosteroid or pharmaceutically acceptable salt thereof a long-acting beta2-adrenergic agonist (LABA) or pharmaceutically acceptable salt thereof and a long-acting muscarinic antagonist (LAMA) or pharmaceutically acceptable salt thereof in combination.
  • LAMA long-acting muscarinic antagonist
  • said corticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof.
  • the said corticosteroid is fluticasone.
  • the said fluticasone salt is fluticasone furoate.
  • the said long-acting beta-2-adrenergic agonist is selected from the group comprising salmeterol, formoterol, arformoterol, salbutamol, indacaterol, terbutaline, metaproterenol, vilanterol, carmoterol, olodaterol, bambuterol, clenbuterol or mixtures thereof.
  • the said long-acting beta-2-adrenergic agonist is vilanterol.
  • the said vilanterol salt is vilanterol trifenatate.
  • the said long-acting muscarinic antagonist is selected from the group comprising tiotropium, aclidinium, darotropium, umeclidinium, glycopyronium, ipratropium or mixtures thereof.
  • the said long-acting muscarinic antagonist is umeclidinium.
  • the said umeclidinium salt is umeclidinium bromide.
  • the dry powder composition comprises;
  • ternary active agent combination is not randomly formulated; on the contrary, they are specifically selected considering their hygroscopic behaviors. They are all non- hygroscopic powders which is essential for the composition subjected to the invention to provide high moisture resistance and stability, fluidity, content uniformity, accordingly.
  • fluticasone furoate is present in an amount of 0.01 to 1 mg, more preferably 0.05 to 0.5 mg in the total composition.
  • the amount of fluticasone furoate is between 0.1 -10%, preferably 0.2-5%, more preferably 0.3-3% by weight of the total composition.
  • vilanterol trifenatate is present in an amount of 0.005 to 0.5 mg, more preferably 0.01 to 0.1 mg in the total composition.
  • the amount of vilanterol trifenatate is between 0.01 -5%, preferably 0.05-3%, more preferably 0.1 -2% by weight of the total composition.
  • umeclidinium bromide is present in an amount of 0.005 to 0.5 mg, more preferably 0.01 to 0.15 mg in the total composition.
  • the amount of umeclidinium bromide is between 0.05-10%, preferably 0.1 -5%, more preferably 0.2-3% by weight of the total composition.
  • the dry powder composition further comprises at least one carrier selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol and maltitol to provide the fluidity of the composition coming out of an inhaler device and to ensure that the active ingredients accurately and consistently reaches the lungs.
  • at least one carrier selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol and maltitol to provide the fluidity of the composition coming out of an inhaler device and to ensure that the active ingredients accurately and consistently reaches the lungs.
  • the composition comprises two different carriers in specified ratios.
  • these two carriers are lactose and mannitol.
  • the composition is free of all types of amino acids such as leucine and all types of stearates such as magnesium stearate. It means that required moisture resistance, stability, fluidity, content uniformity and dosage accuracy are ensured even in absence of a further excipient apart from carrier. It is significantly important considering the prior art and scientific observations in which the use of an amino acid or stearate, especially magnesium stearate, is shown as indispensable to ensure these qualifications.
  • surprisingly high stability and fluidity are provided by the synergistic effect of selectively combined non-hygroscopic active agents, specified weight ratio and specified particle size ratio of selected two carriers which are lactose and mannitol.
  • particle size distribution means the cumulative volume size distribution as tested by any conventionally accepted method such as the laser diffraction method (Malvern analysis).
  • Laser diffraction measures particle size distributions by measuring the angular variation in intensity of light scattered as a laser beam passes through a dispersed particulate sample. Large particles scatter light at small angles relative to the laser beam and small particles scatter light at large angles. The angular scattering intensity data is then analyzed to calculate the size of the particles responsible for creating the scattering. The particle size is reported as a volume equivalent sphere diameter.
  • the d50 value is the size in microns that splits the distribution with half above and half below this diameter. Similarly, 90% of the distribution lies below the D90 value, and 10% of the distribution lies below the D10 value.
  • lactose is present in the composition as the carrier having fine particle size, which means the mean particle size (d50 value) of lactose is in the range of 2-10 pm.
  • mannitol is present in the composition as the carrier having coarse particle size, which means the mean particle size (d50 value) of mannitol is in the range of 75-200 pm.
  • Coarse carrier particles namely mannitol particles, are used to prevent agglomeration of the active agent particles having mean particle size lower than 10 pm.
  • shape and surface roughness of the carrier particles are especially important. Particles having smooth surface will be separated much easier from the active agents compared to the particles in the same size but having high porosity.
  • Active agent particles will tend to concentrate on the regions having higher energy as the surface energy does not dissipate on the coarse carrier particles evenly. This might prevent separation of the active agent particles from the coarse carrier after pulmonary administration, especially in low dose formulations.
  • fine carrier particles namely lactose particles
  • the active agent particles will be attaching to low energy regions; thus, the amount of active agent particles detached from the coarse carrier particles will potentially increase.
  • the amount of the lactose with fine particles is in the range of 1 -15%, more preferably 3-10% by weight of the total composition.
  • the amount of the mannitol with coarse particles is in the range of 85-99%, more preferably 90-97% by weight of the total composition.
  • d50 value of lactose particles is ranging between 4 and 7 pm.
  • d10 value of lactose particles is in the range of 0.5-5 pm, preferably 1 -4 pm.
  • d90 value of lactose particles is in the range of 5-30 pm, preferably 7-15 pm.
  • d50 value of mannitol particles is ranging between 100 and 150 pm.
  • d10 value of mannitol particles is in the range of 2-30 pm, preferably 3-25 pm.
  • d90 value of mannitol particles is in the range of 100-400 pm, preferably 150-350 pm.
  • the d10 value ratio of lactose particles to mannitol particles is in the range of 1 :15 to 1 :100, preferably 1 :20 to 1 :50.
  • the d50 value ratio of lactose particles to mannitol particles is in the range of 1 : 10 to 1 :50, preferably 1 : 15 to 1 :40.
  • the d90 value ratio of lactose particles to mannitol particles is in the range of 1 : 10 to 1 :50, preferably 1 :10 to 1 :30.
  • the weight ratio of lactose to mannitol is in the range of 1 :5 to 1 :100 and preferably 1 :10 to 1 :50. In the most preferred embodiment, this range is 1 :15 to 1 :25.
  • This preferred selection of carriers and their ranges eliminates agglomeration of active agent particles and assures the enhanced stability, moisture resistance, fluidity, content uniformity and dosage accuracy.
  • the dry powder composition subjected to the invention comprises;
  • Example 1 Dry powder composition for inhalation
  • Example 2 Dry powder composition for inhalation
  • Example 3 Dry powder composition for inhalation
  • Example 4 Dry powder composition for inhalation
  • compositions subjected to the invention are prepared by these steps:
  • the dry powder composition subjected to the invention is suitable for administration in dosage forms such as capsules, cartridges or blister packs.
  • the one unit dose of the composition in the dosage form is ranging between 2 to 50 mg.
  • the dry powder composition is presented in one dose capsule.
  • the said capsule may be a gelatin or a natural or synthetic pharmaceutically acceptable polymer such as hydroxypropyl methylcellulose and it is arranged for use in a dry powder inhaler and the composition is configured to be delivered to the lungs by the respiratory flow of the patient via the said inhaler.
  • one dose capsule contains 25 mg dry powder composition.
  • one dose capsule contains 12.5 mg dry powder composition.
  • the dry powder composition subjected is suitable for administration in a multi-dose system, more preferably in a multi-dose blister pack which has more than one blister with air and moisture barrier property.
  • the said blister pack comprises an aluminum material covering them to prevent moisture intake.
  • Each blister is further encapsulated with a material resistant to moisture. By this means, blisters prevent water penetration and moisture intake from outside into the composition.
  • Each blister contains the same amount of active agent and carrier which is provided via content uniformity and dosage accuracy of the composition. For this invention, it is ensured by the specific selection of carriers, their amounts and their mean particle sizes. In a preferred embodiment, a blister contains 5 mg dry powder composition.
  • the said blister pack is arranged to be loaded in a dry powder inhaler and the composition subjected to the invention is configured to be delivered to the lungs via the said inhaler.
  • the inhaler has means to open the blister and to provide respective delivery of each unit dose.
  • the said dry powder inhaler further comprises a lid and a lock mechanism connected to the lid which is arranged to maintain the inhaler locked in both positions in which it is ready for inhalation and the lid is closed.
  • the inhaler also ensures to be automatically re-set once the lid is closed.
  • compositions subjected to the invention are used in the treatment of the respiratory diseases selected from asthma and chronic obstructive pulmonary disease and other obstructive respiratory diseases.
  • the dry powder composition is administered once a day by the said inhaler.
  • the dry powder composition is administered twice a day by the said inhaler.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques de poudre sèche et leur administration au moyen d'inhalateurs dans le traitement de la bronchopneumopathie chronique obstructive (BPCO), de l'asthme et d'autres maladies respiratoires obstructives.
EP18869456.6A 2017-08-21 2018-08-17 Compositions de poudre sèche à inhaler Withdrawn EP3672574A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/12424A TR201712424A2 (tr) 2017-08-21 2017-08-21 Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
PCT/TR2018/050437 WO2019098969A2 (fr) 2017-08-21 2018-08-17 Compositions de poudre sèche à inhaler

Publications (1)

Publication Number Publication Date
EP3672574A2 true EP3672574A2 (fr) 2020-07-01

Family

ID=66218398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18869456.6A Withdrawn EP3672574A2 (fr) 2017-08-21 2018-08-17 Compositions de poudre sèche à inhaler

Country Status (3)

Country Link
EP (1) EP3672574A2 (fr)
TR (1) TR201712424A2 (fr)
WO (1) WO2019098969A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022045995A1 (fr) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de compositions de poudre sèche pour inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539046A (ja) * 2002-08-29 2005-12-22 シプラ・リミテッド 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
TR201000623A2 (tr) * 2010-01-28 2011-08-22 B�Lg�� Mahmut Yeni tiotropyum kombinasyonu.
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2814445A1 (fr) * 2010-10-12 2012-04-19 Cipla Limited Composition pharmaceutique
US20140113888A1 (en) * 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
US9763965B2 (en) * 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
WO2014007767A1 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalateurs de poudre sèche comprenant un excipient autre que le lactose et un composant ternaire
WO2014007769A1 (fr) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprenant un antagoniste du récepteur muscarinique et du glucose anhydre
WO2014007770A2 (fr) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
WO2014007772A2 (fr) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation contenant du glucose anhydre
WO2014007766A1 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalateurs de poudre sèche comprenant un excipient autre que le lactose
GEP201706672B (en) * 2012-07-05 2017-05-25 Arven Ilac Sanayi Ve Ticaret As Dry powder inhaler compositions comprising long acting muscorinic antagonists
ES2959699T3 (es) * 2014-05-28 2024-02-27 Glaxosmithkline Ip Dev Ltd Furoato de fluticasona en el tratamiento de la EPOC

Also Published As

Publication number Publication date
TR201712424A2 (tr) 2019-03-21
WO2019098969A3 (fr) 2019-08-08
WO2019098969A2 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
PT2265258E (pt) Composição destinada a inalação contendo aclidínio para o tratamento de asma
EP2682101B1 (fr) Compositions d'inhalation comprenant du glucose anhydre
EP2682098B1 (fr) Compositions d'inhalation
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
US9987229B2 (en) Process for preparing a medicament
EP2682102A2 (fr) Compositions d'inhalation comprenant du corticostéroïde et du sorbitol
KR20150010757A (ko) 신규한 투약량 및 제형
JP7015549B2 (ja) ７－アゾニアビシクロ［２．２．１］ヘプタン誘導体の乾燥粉末吸入器組成物
EP3672574A2 (fr) Compositions de poudre sèche à inhaler
EA036153B1 (ru) Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор
WO2022045995A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation
WO2022146254A1 (fr) Procédé de préparation de compositions en poudre sèche pour inhalation
WO2023128916A1 (fr) Appareil à grille pour la préparation de compositions de poudre sèche pour inhalation
WO2021080531A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation
WO2022045993A1 (fr) Procédé de production de compositions de poudre sèche pour inhalation
WO2023128918A1 (fr) Procédé comprenant un système de gaz d'alimentation pour préparer des compositions d'inhalation en poudre sèche
WO2024010539A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation à l'aide de différents mélangeurs
WO2022146257A1 (fr) Procédé de préparation de compositions en poudre sèche pour inhalation
WO2022045994A1 (fr) Procédé de préparation de compositions en poudre sèche pour inhalation
WO2024010538A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation à l'aide de différents mélangeurs
WO2022146255A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation
TR2023002207T2 (tr) İnhalasyon i̇çi̇n kuru toz kompozi̇syonlarinin üreti̇m yöntemi̇
TR2022002655T2 (tr) İnhalasyon i̇çi̇n kuru toz kompozi̇syonlarinin hazirlanmasina yöneli̇k bi̇r i̇şlem
TR2023002209T2 (tr) Kuru toz i̇nhalasyon kompozi̇syonlarinin hazirlanmasi i̇çi̇n bi̇r yöntem
EA031373B1 (ru) Способ получения ингаляционных составов

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230808